LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
32 funds hold it · Insiders net selling
Net selling: insiders sold $5.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Financial period
Q3 2026
Earnings per share
$2.20 expected
Revenue
$826.5M expected
Full-Year 2026 guidance
$3.41B to $3.42B
No comparable estimate
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | $2.66est. $2.20 | +21.12%beat | $874.5Mest. $826.5M+5.80% | +8.7%from $804.6M |
| Jun 30, 2026Reported Jul 23, 2026 | $2.37est. $2.08 | +13.86%beat | $872.3MCompany release | +13.8%from $766.5M |
| Mar 31, 2026Reported Apr 23, 2026 | $2.13est. $1.68 | +27.07%beat | $844.9MAlpha Vantage | +21.0%from $698.2M |
| Dec 31, 2025Reported Feb 12, 2026 | $2.04est. $1.83 | +11.54%beat | $805.0MAlpha Vantage | +7.5%from $748.5M |
| Sep 30, 2025Reported Oct 23, 2025 | $1.96est. $1.71 | +14.62%beat | $804.6MSEC filing | +7.7%from $746.9M |
| Jun 30, 2025Reported Jul 24, 2025 | $1.84est. $1.54 | +19.48%beat | $766.5MSEC filing | +9.2%from $702.0M |
| Mar 31, 2025Reported Apr 24, 2025 | $1.45est. $1.26 | +15.08%beat | $698.2MAlpha Vantage | +0.4%from $695.3M |
| Dec 31, 2024Reported Feb 13, 2025 | $1.82est. $1.71 | +6.43%beat | $748.5MAlpha Vantage | +2.2%from $732.1M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $805.0M | $844.9M | $872.3M | $874.5M |
| Cost of what it sold | $501.1M | $548.5M | $543.1M | $527.1M |
| Gross profit | $303.9M | $296.4M | $329.2M | $347.4M |
| What it spent | ||||
| Research and development | $21.8M | $15.8M | $19.7M | $18.3M |
| Sales and admin | $106.5M | $99.5M | $117.6M | $112.9M |
| Other operating costs | $18.5M | $4.0M | $12.8M | -$51.2M |
| Total operating expenses | $146.8M | $119.3M | $150.1M | $80.0M |
| What was left | ||||
| Operating profit | $156.6M | $177.1M | $179.1M | $267.4M |
| Interest on debt | $5.3M | $1.9M | $2.6M | $3.8M |
| Profit before tax | $165.4M | $180.1M | $180.1M | $267.7M |
| Tax | $33.3M | $44.7M | $32.2M | $58.0M |
| Net profit | $132.1M | $138.8M | $154.0M | $214.0M |
| EBITDA | $209.5M | $218.5M | $225.3M | $313.6M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoAS
Leans bullishNov 10Bancorp Targets Higher Earnings as Fintech Lending Expands
Leans bullishNov 9How Investors Are Reacting To West Pharmaceutical Services Stock After Raised Outlook
BullishNov 8West Pharmaceutical stock gets higher 2026 outlook after Q3 growth
BullishNov 8West Pharmaceutical Services (WST) Raises 2026 Outlook On Earnings Strength As Fair Value Debate Builds
Leans bullishNov 6Here's Why You Should Retain MMSI Stock in Your Portfolio for Now
Leans bullishNov 6West Pharmaceutical Raises Outlook as Earnings Surge 57%
BullishNov 6Two holders report the same 8.5% stake in West Pharmaceutical (WST).
NeutralNov 534 macro signals shaping WST right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
